These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842 [TBL] [Abstract][Full Text] [Related]
27. Influence of dystrophin-gene mutation on mdx mouse behavior. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks. Vaillend C; Rendon A; Misslin R; Ungerer A Behav Genet; 1995 Nov; 25(6):569-79. PubMed ID: 8540895 [TBL] [Abstract][Full Text] [Related]
28. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy. Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607 [TBL] [Abstract][Full Text] [Related]
29. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy. Ito M; Ehara Y; Li J; Inada K; Ohno K Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975 [TBL] [Abstract][Full Text] [Related]
30. Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. Rafael JA; Nitta Y; Peters J; Davies KE Mamm Genome; 2000 Sep; 11(9):725-8. PubMed ID: 10967129 [TBL] [Abstract][Full Text] [Related]
31. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy. Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208 [TBL] [Abstract][Full Text] [Related]